蔡

蔡郑东 (Zhengdong Cai)

guizhou university

H指数:32

被引数:3,948

个人简介

"学科代码：100210 性别：男学科名称：外科学培养单位：附属第一人民医院三级学科：骨外专业领域名称：外科学专业学位联系方式：上海市海宁路100号专业领域代码：105111 邮编：200080"

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The PmRDUF1-PmMYB30-PmLAS Regulatory Module Is Involved in Terpenoid Biosynthesis of Pinus massoniana

PmRDUF1-PmMYB30-PmLAS调控模块参与<i>Pinus massoniana</i>的萜类生物合成

Physiologia Plantarum

IF3.6

2026-09-100

PRE

Subcutaneous pedicle island flap for complex congenital earlobe cleft correction

International Journal of Oral and Maxillofacial Surgery

IF2.7

2025-10-010

PRE

Clinical-proteomic classification and precision treatment strategy of chordoma

CELL REPORTS MEDICINE

IF10.6

2024-10-010

OAAI

Enhanced Osteosarcoma Immunotherapy via CaCO3 Nanoparticles: Remodeling Tumor Acidic and Immune Microenvironment for Photodynamic Therapy

通过CaCO3纳米颗粒增强骨肉瘤免疫治疗: 重塑肿瘤酸性和免疫微环境用于光动力治疗

ADVANCED HEALTHCARE MATERIALS

IF9.6

2024-06-161

PRE

Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway

EUROPEAN JOURNAL OF PHARMACOLOGY

IF4.7

2023-03-019

PRE

ML216-Induced BLM Helicase Inhibition Sensitizes PCa Cells to the DNA-Crosslinking Agent Cisplatin

MOLECULES

IF4.6

2022-12-121

OAAI

Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment

多组学分析确定具有不同预后的骨肉瘤亚型，表明分层治疗

NATURE COMMUNICATIONS

IF15.7

2022-11-2340

OAAI

Pectolinarigenin acts as a potential anti-osteosarcoma agent via mediating SHP-1/JAK2/STAT3 signaling

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2022-09-0111

PRE

CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma

CDK7/GRP78信号轴在骨肉瘤生长和转移中的作用

ONCOGENE

IF7.3

2022-08-3012

PRE

Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-06-0168

OAAI

Identification of two immune subtypes in osteosarcoma based on immune gene sets

基于免疫基因集的骨肉瘤两种免疫亚型的鉴定

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2021-07-019

PREAI

Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling

FRONTIERS IN ONCOLOGY

IF3.3

2021-06-0814

OAAI

MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma

MYLK4通过激活骨肉瘤表皮生长因子受体信号促进肿瘤进展

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

IF12.8

2021-05-129

OAAI

RETRACTION: Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition (Retraction of Vol 7, art no E2421, 2016)

CELL DEATH & DISEASE

IF9.6

2021-03-150

OAAI

Her4 promotes cancer metabolic reprogramming via the c-Myc-dependent signaling axis

CANCER LETTERS

IF10.1

2021-01-0125

PREAI

Inhibition of HDACs-EphA2 signaling axis with WW437 demonstrates promising preclinical antitumor activity in breast cancer (vol 31, pg 276, 2018)

EBIOMEDICINE

IF10.8

2020-02-011

OAAI

Sarcoma-Targeting Peptide-Decorated Polypeptide Nanogel Intracellularly Delivers Shikonin for Upregulated Osteosarcoma Necroptosis and Diminished Pulmonary Metastasis (vol 8, pg 1361, 2018)

THERANOSTICS

IF13.3

2020-01-013

OAAI

Surgical resection and reconstructive techniques using autologous femoral head bone-grafting in treating partial acetabular defects arising from primary pelvic malignant tumors

BMC CANCER

IF3.4

2019-10-1813

OAAI

Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3 (vol 36, pg 6627, 2017)

ONCOGENE

IF7.3

2019-02-151

OAAI

Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2019-02-15119

OAAI

蔡郑东 (Zhengdong Cai)

个人简介

教育背景

工作经历

荣誉奖项

研究方向